PhRMA CEO Steve Ubl discusses, PBM reform, the "pill penalty" with the administration and advocating for pharmaceutical ...
The bill would tie prescription drug prices to federally negotiated rates under a program passed in the 1990s.
When the 340B program was first launched, pharmaceutical manufacturers were to provide medications at a discounted price for ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
House Democrats beat back a series of Republican amendments on party-line votes Wednesday, setting up a final vote on a ...
While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...
Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
It’s time to level the playing field, empower patients, and protect access both to medicines and to our local pharmacies. Let’s work together to bring accountability and transparency to drug pricing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback